Betacoronavirus MRNA vaccines
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
1. A method of vaccinating a human subject against a betacoronavirus, the method comprising administering to the human subject a dose of a vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus spike protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, wherein the dose comprises from 20-50 μg of the mRNA and is administered intramuscularly.
2. The method of claim 1 , wherein the dose comprises 20 μg of the mRNA.
3. The method of claim 1 , wherein the dose comprises 25 μg of the mRNA.
4. The method of claim 1 , wherein the dose comprises 30 μg of the mRNA.
5. The method of claim 1 , wherein the dose comprises 50 μg of the mRNA.
6. A method of vaccinating a human subject against a betacoronavirus, the method comprising administering to the human subject a dose of a vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus spike protein, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine, wherein the dose comprises from 10-15 μg of the mRNA and is administered intramuscularly.
7. The method of claim 6 , wherein the dose comprises 10 μg of the mRNA.
8. A method of vaccinating a human subject against a betacoronavirus, the method comprising administering to the human subject a dose of a vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid, wherein the mRNA comprises an open reading frame encoding a full-length betacoronavirus spike protein, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine, wherein the dose comprises from 10-100 μg of the mRNA and is administered intramuscularly.